Gliflozin shows efficacy in elderly patients with T2D

  • Giugliano D & al.
  • Diabetes Res Clin Pract
  • 9 mar. 2020

  • de Miriam Tucker
  • Clinical Essentials
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Takeaway

  • The efficacy of gliflozins (sodium-glucose cotransporter-2 inhibitors) in patients with type 2 diabetes (T2D) is unchanged by age and not dependent on concomitant statin use.

Why this matters

  • Clinical data on the effects of glucose-lowering drugs on cardiovascular events in the elderly are limited.
  • Avoidance of medications that may cause hypoglycemia is advised in elderly populations.

Study design

  • Meta-analysis of data from 3 industry-sponsored cardiovascular outcome trials of gliflozins and 2 subanalyses, involving 34,323 patients with T2D of whom 49.8% were age ≥65 years and 75.3% were taking statins.
  • Funding: “Associazione Salute con Stile” and “PreVenENDO.”

Key results

  • HRs for major adverse cardiovascular events (MACE):
    • 0.95 (95% CI, 0.86-1.05) for
    • 0.83 (0.71-0.96) for ≥65 years (P=.15).
  • HRs for MACE:
    • 0.87 (95% CI, 0.81-0.94) for those taking a statin vs 
    • 0.88 (95% CI, 0.77-1.01) for those not taking a statin (P=.90).

Limitations

  • Meta-analysis limitations.